• Bishop, J., Matthews, J., Young, G., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M. & Fox, R. (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 87, 1710.
  • Bradstock, K.F., Matthews, J.P., Lowenthal, R.M., Baxter, H., Catalano, J., Brighton, T., Gill, D., Eliadis, P., Joshua, D. & Cannell, P. (2005) A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood, 105, 481488.
  • Braess, J., Spiekermann, K., Staib, P., Grüneisen, A., Wörmann, B., Ludwig, W.-D., Serve, H., Reichle, A., Peceny, R., Oruzio, D., Schmid, C., Schiel, X., Hentrich, M., Sauerland, C., Unterhalt, M., Fiegl, M., Kern, W., Buske, C., Bohlander, S., Heinecke, A., Baurmann, H., Beelen, D.W., Berdel, W.E., Büchner, T. & Hiddemann, W. (2009) Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood, 113, 39033910.
  • Burnett, A.K., Hills, R.K., Wheatley, K., Goldstone, A.H., Prentice, A.G. & Milligan, D. (2006) A sensitive risk score for directing treatment in younger patients with AML. Blood (ASH Annual Meeting Abstracts), 108, 18.
  • De Jonge, H.J.M., Valk, P.J.M., De Bont, E.S.J.M., Schuringa, J.J., Ossenkoppele, G., Vellenga, E. & Huls, G. (2011) Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica, 96, 13101317.
  • Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R. & Burnett, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood, 92, 2322.
  • How, J., Sykes, J., Gupta, V., Yee, K.W.L., Schimmer, A.D., Schuh, A.C., Minden, M.D., Kamel-Reid, S. & Brandwein, J.M. (2012) Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer, 118, 61106117.
  • Juliusson, G., Antunovic, P., Derolf, Å., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wahlin, A. & Höglund, M. (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, 113, 41794187.
  • Pfirrmann, M., Ehninger, G., Thiede, C., Bornhäuser, M., Kramer, M., Röllig, C., Hasford, J. & Schaich, M. (2011) Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. The Lancet Oncology, 13, 207214.
  • Ravandi, F., Cortes, J., Faderl, S., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Santos, F.P.S., Shan, J., Brandt, M., de Lima, M., Pierce, S. & Kantarjian, H. (2010) Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood, 116, 58185823.